

**Table 3.** Type of adverse effects.

|                             | <b>Alendronate</b> | <b>Etidronate</b> | <b>Risedronate</b> |
|-----------------------------|--------------------|-------------------|--------------------|
|                             | <b>N (%)</b>       | <b>N (%)</b>      | <b>N (%)</b>       |
| Numbers of patients treated | 710                | 181               | 130                |
| Patients with AEs           | 179                | 20                | 27                 |
| GI system AEs               | 149 (83.3)         | 18 (90.0)         | 20 (74.1)          |
| upper GI system AEs         | 134 (74.9)         | 16 (80.0)         | 17 (63.0)          |
| lower GI system AEs         | 15 (8.4)           | 2 (10.0)          | 3 (11.1)           |
| Non-GI system AEs           | 30 (16.8)          | 2 (10.0)          | 7 (25.9)           |
| allergic reaction           | 7 (3.9)            | 1 (5.0)           | 1 (3.7)            |
| bone pain                   | 8 (4.5)            | 0 (0.0)           | 2 (7.4)            |
| arthralgia                  | 7 (3.9)            | 0 (0.0)           | 1 (3.7)            |
| myalgia                     | 1 (0.6)            | 0 (0.0)           | 1 (3.7)            |
| other                       | 7 (3.9)            | 1 (5.0)           | 2 (7.4)            |

AEs: adverse effects, GI: gastro-intestinal. Data are presented as absolute values (percentage).